79 related articles for article (PubMed ID: 31205208)
1. A Success Story: Advances in Treatment and Lower Disease Prevalence of Hepatitis C Has a Large Impact on Medical Plan Costs.
Leung N; Bernacki SE; Bernacki EJ
J Occup Environ Med; 2019 Aug; 61(8):e354-e357. PubMed ID: 31205208
[TBL] [Abstract][Full Text] [Related]
2. Economic burden associated with patients diagnosed with hepatitis C.
McCombs JS; Yuan Y; Shin J; Saab S
Clin Ther; 2011 Sep; 33(9):1268-80. PubMed ID: 21840056
[TBL] [Abstract][Full Text] [Related]
3. Cost burden of hepatitis C virus treatment in commercially insured patients.
Lu CY; Ross-Degnan D; Zhang F; LeCates R; Lupton C; Sherman M; Wagner A
Am J Manag Care; 2019 Dec; 25(12):e379-e387. PubMed ID: 31860232
[TBL] [Abstract][Full Text] [Related]
4. Effect of Carving in Pharmacy Benefits on Utilization and Costs.
Parekh N; Papa S; Drnach A; Spiegel L; Huang Y; Manolis C; Good CB
J Manag Care Spec Pharm; 2020 Oct; 26(10):1317-1324. PubMed ID: 32996397
[TBL] [Abstract][Full Text] [Related]
5. Burden of illness of hepatitis C from a managed care organization perspective.
Armstrong EP; Charland SL
Curr Med Res Opin; 2004 May; 20(5):671-9. PubMed ID: 15140332
[TBL] [Abstract][Full Text] [Related]
6. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
Wasitthankasem R; Vichaiwattana P; Siripon N; Posuwan N; Auphimai C; Klinfueng S; Thanetkongtong N; Vuthitanachot V; Saiyatha S; Thongmai C; Sochoo S; Pongsuwan N; Poovorawan K; Tangkijvanich P; Poovorawan Y
PLoS One; 2018; 13(4):e0196301. PubMed ID: 29689073
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort.
Maier MM; Zhou XH; Chapko M; Leipertz SL; Wang X; Beste LA
Dig Dis Sci; 2018 Jun; 63(6):1454-1462. PubMed ID: 29453610
[TBL] [Abstract][Full Text] [Related]
8. A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System.
Nguyen JT; Rich JD; Brockmann BW; Vohr F; Spaulding A; Montague BT
J Urban Health; 2015 Aug; 92(4):635-49. PubMed ID: 25828149
[TBL] [Abstract][Full Text] [Related]
9. Association of Direct-Acting Antiviral Therapy for Hepatitis C With After-Treatment Costs Among Medicare Beneficiaries.
Jung J; Feldman R; Kalidindi Y; Riley T
JAMA Netw Open; 2020 Jun; 3(6):e208081. PubMed ID: 32602909
[TBL] [Abstract][Full Text] [Related]
10. NIH Consensus Statement on Management of Hepatitis C: 2002.
NIH Consens State Sci Statements; 2002 Jun 10-12; 19(3):1-46. PubMed ID: 14768714
[TBL] [Abstract][Full Text] [Related]
11. Effects of Health Insurance Among Patients on Hepatitis C Treatment Along the Texas-Mexico Border.
Romero R; Campbell L; Song H; Zuckerman MJ; Alozie O
Gastroenterol Nurs; 2016; 39(4):310-6. PubMed ID: 27467060
[TBL] [Abstract][Full Text] [Related]
12. An examination of periodontal treatment and per member per month (PMPM) medical costs in an insured population.
Albert DA; Sadowsky D; Papapanou P; Conicella ML; Ward A
BMC Health Serv Res; 2006 Aug; 6():103. PubMed ID: 16914052
[TBL] [Abstract][Full Text] [Related]
13. Costs and cost-effectiveness of different follow-up schedules for detection of occupational hepatitis C virus infection.
Deuffic-Burban S; Abiteboul D; Lot F; Branger M; Bouvet E; Yazdanpanah Y
Gut; 2009 Jan; 58(1):105-10. PubMed ID: 18824553
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
[TBL] [Abstract][Full Text] [Related]
15. A tool to measure the impact of inaction toward elimination of hepatitis C: A case study in Korea.
Won YK; Kang KS; Gonzalez YS; Razavi H; Dugan E; Han KH; Ahn SH; Jeon MY; Kim DY
PLoS One; 2020; 15(4):e0232186. PubMed ID: 32343727
[TBL] [Abstract][Full Text] [Related]
16. Long-term disease and economic outcomes of prior authorization criteria for Hepatitis C treatment in Pennsylvania Medicaid.
Kabiri M; Chhatwal J; Donohue JM; Roberts MS; James AE; Dunn MA; Gellad WF
Healthc (Amst); 2017 Sep; 5(3):105-111. PubMed ID: 27932263
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of novel treatment of hepatitis C virus in Lebanese patients.
Nasser SC; Mansour H; Abi Nader T; Metni M
Int J Clin Pharm; 2018 Jun; 40(3):693-699. PubMed ID: 29611014
[TBL] [Abstract][Full Text] [Related]
18. Health care, treatment patterns and cost of services for patients infected with chronic hepatitis C virus in a large insured New England population.
Rosenberg DM; Cook SF; Lanza LL
J Viral Hepat; 2000 Sep; 7(5):361-7. PubMed ID: 10971824
[TBL] [Abstract][Full Text] [Related]
19. Should we treat acute hepatitis C? A decision and cost-effectiveness analysis.
Bethea ED; Chen Q; Hur C; Chung RT; Chhatwal J
Hepatology; 2018 Mar; 67(3):837-846. PubMed ID: 29059461
[TBL] [Abstract][Full Text] [Related]
20. Assessing the burden of illness of chronic hepatitis C and impact of direct-acting antiviral use on healthcare costs in Medicaid.
Roebuck MC; Liberman JN
Am J Manag Care; 2019 Jun; 25(8 Suppl):S131-S139. PubMed ID: 31211526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
